Evidence map›Paper›PMID 41811887›Full record

ArticleJournal of immunology research2026

Combining Activation-Induced Markers With PD-L1 Selectively Enhances Detection of Antigen-Specific T Cells in Virus-Infected Individuals.

Christine Kreher, Laura Y L Kummer, Maryse Tempert, Veronique A L Konijn, Gertjan Wolbink, Filip Eftimov, Taco W Kuijpers, Theo Rispens, S Marieke van Ham, Anja Ten Brinke

Abstract read
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christine KreherSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, uva.nl.ORCID https://orcid.org/0000-0002-8524-0622
Laura Y L KummerSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, uva.nl.ORCID https://orcid.org/0009-0008-1575-2973
Maryse TempertSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, uva.nl.
Veronique A L KonijnSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, uva.nl.
Gertjan WolbinkAmsterdam Rheumatology and Immunology Center, Amsterdam UMC, Location Reade, Amsterdam, Netherlands, amc.nl.ORCID https://orcid.org/0000-0003-1924-7460
Filip EftimovDepartment of Neurology and Neurophysiology, Amsterdam UMC, Location AMC, Amsterdam, Netherlands, amc.nl.ORCID https://orcid.org/0000-0002-0146-0776
Taco W KuijpersDepartment of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, Amsterdam, Netherlands, amc.nl.ORCID https://orcid.org/0000-0002-7421-3370
Theo RispensSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, uva.nl.ORCID https://orcid.org/0000-0001-9600-1312
S Marieke van HamSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, uva.nl.ORCID https://orcid.org/0000-0003-1999-9494
Anja Ten BrinkeSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, uva.nl.ORCID https://orcid.org/0000-0002-0135-7496

Funding

European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie 860003ZonMw 10430072010007
6 · The paper itself

Abstract

Detection and characterization of antigen-specific T cells are important for studying immune responses upon infection, vaccination, or autoreactivity. The activation-induced marker (AIM) assay is a robust technique to identify and characterize antigen-specific CD4 and CD8 T cells. However, there is variability in the AIM assay, particularly in the type and number of activation markers used. In this study, we set out to define which marker combinations are most suited to optimally detect antigen-specific CD4 and CD8 T cells and if certain marker combinations preferentially detect specific CD4 T helper subsets. A multiparameter flow cytometry panel, including six common activation markers: CD40L, CD137, CD69, OX40, CD25, and PD-L1, was used for detecting antigen-specific T cells following infection (SARS-CoV-2 and CMV) or vaccination (mRNA-1273 SARS-CoV-2). We demonstrate that combining multiple activation markers increases the detection frequency of antigen-specific CD4 T cells compared to commonly used dual marker combinations. In addition, marker combinations including PD-L1 detected a higher frequency of antigen-specific CD4 T cells in SARS-CoV-2 and CMV infected but not in SARS-CoV-2-vaccinated individuals. Certain dual marker combinations preferentially detected specific CD4 T helper subsets. The majority of antigen-specific CD8 T cells were captured by the dual combination of CD69 plus CD25. In conclusion, combining CD137, CD69, OX40, CD25, and PD-L1 in an AIM assay results in robust and optimal detection of both specific CD4 T helper subsets and CD8 T cells in different antigenic contexts.

Indexed as

B7-H1 AntigenCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19Cytomegalovirus InfectionsSARS-CoV-2Antigens, CDAntigens, Differentiation, T-LymphocyteBiomarkersCD40 LigandCD69 AntigensCytomegalovirusFlow CytometryHumansInterleukin-2 Receptor alpha SubunitLectins, C-TypeAntigens, CDAntigens, Differentiation, T-LymphocyteB7-H1 AntigenBiomarkersCD274 protein, humanCD40 LigandCD69 AntigensIL2RA protein, humanInterleukin-2 Receptor alpha SubunitLectins, C-TypeReceptors, OX40TNFRSF4 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 9AIMBoolean gatingCD4CD8CMVSARS-CoV-2T helper cellsvaccination

Identifiers

PMID41811887
PMCPMC13140888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.